Could This be Pfizer's Best Incoming Drug?

Pfizer  (NYSE: PFE  ) 's pipeline has been the subject of much speculation (and some derision) lately as the company has been spotlighted in its attempts to juice growth by purchasing British pharma AstraZeneca. But there are exciting opportunities in Pfizer's pipeline -- for example: Bococizumab, the PCSK9 inhibitor that has lots of investors excited. Even so, there is one drug that really seems to stand out as perhaps the most exciting opportunity in Pfizer's pipeline: Breast cancer drug palbociclib, which was recently submitted for FDA approval.

And in the video below, from Where The Money Is, the Motley Fool's investing show, health care analysts Michael Douglass and David Williamson lay out the potential opportunity for palbociclib and why investors are so excited about the drug. 

Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On May 29, 2014, at 3:32 PM, captainern wrote:

    i'm not sure what the best incoming drug is but I sure know that Lipitor is the best outgoing, preceded by Feldene, Procardia, Norvasc et al.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2976042, ~/Articles/ArticleHandler.aspx, 9/1/2015 12:26:29 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Michael Douglass

As the Motley Fool's Health Care Editor/Analyst, I focus on all things health care -- although my greatest interest is in the megatrends reshaping the American health care system, including the Affordable Care Act, Accountable Care Organizations, a shifting regulatory landscape, and the new drug discoveries fundamentally changing disease management and treatment.

Today's Market

updated Moments ago Sponsored by:
DOW 16,175.13 -352.90 -2.14%
S&P 500 1,931.94 -40.24 -2.04%
NASD 4,690.58 -85.93 -1.80%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/1/2015 12:10 PM
PFE $31.79 Down -0.43 -1.33%
Pfizer CAPS Rating: ****